ライフサイエンスコーパス: TTV

1 TTV and ETV, as well as the largest enhancing tumor diam

2 TTV contamination was found in ten (56%) of 18 batches o

3 TTV did not worsen the biochemical severity (mean ALT: 5

4 TTV DNA persisted in serum samples taken up to 6 years a

5 TTV DNA sequencing of nine isolates showed the same geno

6 TTV DNA was detected in 96% of tested serum samples.

7 TTV DNA was detected in the blood of 69%, 71%, and 64% o

8 TTV helped predict contributory status, with an AUC of 0

9 TTV infection is widespread, and its replication is clos

10 TTV infection was detected in four (19%) of 21 patients

11 TTV infection was present in 1% (1 of 100) of blood dono

12 TTV infection was sought by detection of TTV DNA in seru

13 TTV is a prospective biomarker for risk stratification o

14 TTV levels >1 x 106 copies/mL exclude rejection with a s

15 TTV load at the time of biopsy was lower in recipients w

16 TTV load before vaccination was with a median (interquar

17 TTV load is associated with rejection and infection in s

18 TTV load reflects changes in immunosuppressive therapy e

19 TTV load was associated with immunodeficiency in PLWH.

20 TTV load was quantified before, 4 wk, and 3 mo postvacci

21 TTV load was related to the immune status in patients af

22 TTV may not be a primary hepatitis virus.

23 TTV viraemia is frequent in the blood-donor population,

24 TTV viraemia was detected in 19 (1.9%) of 1000 non-remun

25 TTV was analyzed in the context of protocol biopsies (n

26 TTV was found in 7.5% of 402 donors and in 11.0% of 347

27 TTV(bone) was higher in patients with new extraosseous m

28 TTVs can provide precise, but complex, constraints on pl

29 p = 0.003), enhancing tumor area (p = 0.03), TTV (p = 0.03), and ETV (p = 0.01).

30 Comparison of the sensitivities of 2 TTV polymerase chain reaction (PCR) primer sets showed t

31 NV isolates, 6 prototype TTV isolates, and 7 TTV variants (including SANBAN, TUS01, PMV, and YONBAN).

32 A TTV load <1 x 106 copies/mL suggests suboptimal immunosu

33 as associated with the number of days with a TTV load <1 x 106 copies/mL between months 3 and 12 post

34 Patients with a higher absolute TTV at the start of cycle 2 had worse PSA progression-fr

35 PSA level (r = 0.55 and 0.56), but absolute TTVs did not correlate significantly (r = 0.00 and 0.18)

36 The risk of acquiring TTV alone was only slightly higher in recipients of unmo

37 The high prevalence of active TTV infection in the general population, both in the UK

38 The finding of the additional TTV-related species should be taken into consideration w

39 Additionally, TTV-DNA levels decreased significantly before biopsy-pro

40 a higher median number of alphatorquevirus (TTV) species in participants with persistent viremia com

41 Although TTV control is driven by T cells, other major immune com

42 Although TTV(bone) and ALP correlated at baseline, changes in TTV

43 We used semi-nested PCR to amplify TTV DNA from serum samples from 126 adults, of whom 72 w

44 correlation between total anelloviruses and TTV DNA levels.

45 This suggests that GBV-C and TTV may have different routes of transmission.

46 tected multiple subtypes of the BKV, JCV and TTV.

47 nship between alanine transaminase level and TTV DNA level was observed in 4 patients with long-term,

48 Correlations between TF and TTV were assessed using regression models and Spearman c

49 CNN-predicted TTC and TTV had an area under the receiver operating characteris

50 Model-predicted TTC and TTV measurements were compared with MRI-based measuremen

51 CNN predicted to measured change in TTC and TTV over the course of NAC, the concordance correlation

52 ruses highly divergent from both the TTV and TTV-like minivirus groups.

53 The metastatic site, histology type, and TTV were used to predict liquid biopsy contributory stat

54 Patient-based TTV may be preferred for multicenter studies because its

55 We found no association between TTV and non-A to E hepatitis and no effect of TTV on the

56 is trial demonstrates an association between TTV and subclinical graft rejection in kidney transplant

57 o consideration when the association between TTV infections and human diseases of unknown etiology is

58 suggests an independent association between TTV level and alloreactivity.

59 To assess the association between TTV load in the peripheral blood and AMR, 715 kidney tra

60 We studied the association between TTV viremia and biochemical evidence of hepatitis in blo

61 le databases did not reveal identity between TTV and other viruses.

62 s were also shown to be greater than between TTV genotypes.

63 Between TTVs, improved Doppler surveys, high-contrast imaging ca

64 We evaluated associations between TTVs and the appearance of NLs at cycles 2 and 3 with su

65 Total tumor volume within bone (TTV(bone)) was determined on (68)Ga-PSMA PET/CT.

66 ncy editing occurs even at the non-canonical TTV PAM sites.

67 The expression profile of the circovirus TTV has not yet been fully characterized.

68 Of 21 viremic subjects, 67% cleared TTV within 5 years (38% in 1 year); 33% were viremic thr

69 Our analysis confirmed TTV as a strong predictor of CD4+ T-cell count and CDC c

70 to sequences derived from the corresponding TTV genome region deposited in GenBank.

71 iteria, alpha-fetoprotein, up-to-7 criteria, TTV, and platelet count were predictors of successful do

72 For (68)Ga-PSMA PET/CT, TTV(bone) at baseline was lower in good responders than

73 reaction (PCR) protocols were used to detect TTV DNA in sera of persons infected with hepatitis C vir

74 AnelloScan detected TTV-specific antibodies among all study participants.

75 We detected TTV by PCR using primers from a conserved region in the

76 We detected TTV DNA in 18 (25%) of the 72 patients with chronic live

77 onstrated that genome sequences of different TTV strains are significantly divergent.

78 ral DNAemia with at least 1 virus (excluding TTV) was detected in 191 patients (47.6%) overall, 63 of

79 ax) was reduced in 51% (18/35) and (18)F-FDG TTV in 67% (22/35).

80 An (18)F-FDG TTV increase by more than 30% was associated with a shor

81 for individual lesion volumes and 17.0% for TTV.

82 area, 0.58 (95%CI: 0.34-0.98, p = 0.04) for TTV, and 0.52 (95%CI: 0.30-0.91, p = 0.02) for ETV.

83 78), with an optimal cutoff of 151 cm(3) for TTV and a TF cutoff of 10%.

84 polymerase chain reaction are available for TTV quantification.

85 UV(mean), with higher variation observed for TTV.

86 Of the 123 patients who tested positive for TTV, significant numbers were also infected with human h

87 ESINA multicenter cohort were reanalyzed for TTV.

88 raft biopsies and adequately stored sera for TTV quantification by polymerase chain reaction.

89 This trend was striking for TTV and TTMDV and very modest for TTMV in both plasma an

90 an S epidermidis detected by WGS or DNA from TTV by qPCR in ocular fluids is associated with worse ou

91 blood-borne viruses tested, whereas 15% had TTV alone.

92 had TTV and hepatitis C virus (HCV), 22% had TTV, and at least 2 of the 4 known human blood-borne vir

93 human immunodeficiency virus (HIV): 31% had TTV and hepatitis C virus (HCV), 22% had TTV, and at lea

94 High TTV viremia is not associated with hepatitis after OLT,

95 Higher TTV-DNA levels reflect more intense immunosuppression, w

96 In multivariate analysis, a higher TTV and the appearance of NLs at the start of cycles 2 a

97 In a generalized linear model, higher TTV levels were associated with a decreased risk for AMR

98 Conclusion: Higher TTVs and NLs on LuPSMA SPECT/CT at the start of cycles 2

99 Hitherto TTV load has not been used in interventional settings, b

100 Human TTV's are epidemiologically associated with several huma

101 Furthermore, an anti-genogroup 1 human TTV antiserum did not react with any of the three TTSuV

102 mined human and swine sera by swine or human TTV-specific PCRs, to determine whether swine TTVs (TTSu

103 versely, liver inflammatory activity impairs TTV replication.

104 ALT was 182 in those TTV-positive and 302 in TTV-negatives.

105 n the biochemical severity (mean ALT: 537 in TTV+; 550 in TTV-) or persistence of hepatitis C.

106 ical severity (mean ALT: 537 in TTV+; 550 in TTV-) or persistence of hepatitis C.

107 cted to examine the association of change in TTV (continuous and >30%), SUV(max), PSA, and radiograph

108 The change in TTV between dose 1 and 2 [(177)Lu]Lu-PSMA SPECT/CT predi

109 qualitatively by five readers for changes in TTV and for new lesions.

110 Changes in TTV measured at the start of cycles 2 and 3 relative to

111 isual RECIP and with quantitative changes in TTV to determine quantitative RECIP.

112 ons was combined with qualitative changes in TTV to determine visual RECIP and with quantitative chan

113 Quantitative changes in TTV were also measured using tumor segmentation software

114 ) and ALP correlated at baseline, changes in TTV(bone) and ALP on treatment did not.

115 ients, was not correlated with a decrease in TTV(bone), which might make one question the value of AL

116 Sensitivity of a 10-fold decrease in TTV-DNA levels for a subsequent rejection episode was 0.

117 ection (n = 63) whereby each log increase in TTV copies/mL decreased the risk for rejection by 9% (ri

118 CR, this virucidal step seemed to inactivate TTV infectivity.

119 f prognostic and predictive models including TTV, NLs, and PSA changes is warranted.

120 be more evolutionary distant from all known TTV sequences.

121 Conclusion: mCRPC patients with lower TTV(bone) on (68)Ga-PSMA PET/CT have the best clinical o

122 es demonstrated the existence of three major TTV genotypes.

123 nellovirus are known to infect humans, named TTV, TTMDV, and TTMV.

124 Neither TTV nor HIV load were predictive for the clinical catego

125 The rate of new TTV infections in 13 patients with non-A to E hepatitis

126 The rate of new TTV infections was 4.7% in 127 nontransfused, and 26.4%

127 s inversely correlated with HIV load but not TTV load.

128 nsplant patients have proposed assessment of TTV load for risk stratification of clinically overt gra

129 o clarify whether longitudinal assessment of TTV load might predict AMR risk and help guide the type

130 blood and blood products, and assessment of TTV's aetiological role in hepatic and extra-hepatic dis

131 biophysical and molecular characteristics of TTV suggest that it is a member of a new family of virus

132 as used to propose a first classification of TTV load with regard to clinical stage.

133 transfection of a full-length viral clone of TTV genotype 6, each of the three virally encoded mRNAs

134 whereas the TTV-DNA kinetic (ie, decrease of TTV-DNA levels) indicate rejection.

135 TTV infection was sought by detection of TTV DNA in serum by polymerase chain reaction (PCR) usin

136 atment had little effect on the detection of TTV in factor VIII and IX by PCR, this virucidal step se

137 ur results do not suggest a causal effect of TTV on chronic liver disease in these patients.

138 TV and non-A to E hepatitis and no effect of TTV on the severity or duration of coexistent hepatitis

139 currently testing the safety and efficacy of TTV-guided immunosuppression.

140 ients increased, so too did the frequency of TTV and TTMDV detection.

141 We investigated the frequency of TTV viraemia in UK blood donors, and the extent to which

142 Additionally, five new groups of TTV sequences were identified.

143 Finally, intravenous inoculation of TTV-positive human serum into chimpanzees demonstrated t

144 ur objective was to describe the kinetics of TTV DNA loads and their association with critical illnes

145 reactivity decreased by 10% per log level of TTV copies/mL (risk ratio, .90 [95% confidence interval,

146 assification (n = 33) showed lower levels of TTV in the peripheral blood compared to patients without

147 The majority of TTV-positive cases had no biochemical or histological ev

148 Test performance of TTV load does not allow for the diagnosis of rejection a

149 Presence of TTV at presentation was associated with a higher rate of

150 The presence of TTV viral DNA was confirmed in 7 cases by qPCR.

151 on primers were used to test for presence of TTV, which was found in approximately 10% of US voluntee

152 s and to further determine the prevalence of TTV infection in several groups of patients with liver d

153 cantly underestimated the true prevalence of TTV.

154 The rate of TTV DNA was similar among patients with various liver di

155 The rate of TTV infection among US non-A, non-B, non-C, non-D, non-E

156 (68)Ga-PSMA response of TTV(bone) showed intrapatient heterogeneity in most pati

157 cts was associated with an increased risk of TTV infection (relative risk, 4.5; 90% confidence interv

158 vestigated the possible aetiological role of TTV in cryptogenic fulminant hepatic failure (FHF).

159 The role of TTV in liver disease has not been established.

160 tudies are required to determine the role of TTV in the pathogenicity of acute and/or chronic liver d

161 blood-donor population, and transmission of TTV through transfusion of blood components may have occ

162 The value of TTV quantification in the context of subclinical rejecti

163 Time-associated variations of TTV and anellovirus DNA loads were observed.

164 The common occurrence of TTVs as environmental contaminants and the increasing in

165 e for possible cross-species transmission of TTVs.

166 ce of immunosuppression and HEV infection on TTV replication and liver injury in pediatric patients a

167 ntly more genetically related than any other TTV genotype.

168 ss-sectional AMR screening and, in parallel, TTV quantification.

169 r potential confounders (risk ratio 0.94 per TTV log level; 95% confidence interval 0.90-0.99; P = 0.

170 bjected to per-protocol monitoring of plasma TTV.

171 TF helped predict TTV with the linear model (R(2) = 0.17; rho = 0.41; P <

172 Prototype TTV formed group 2, PMV formed group 3, and SENV, SANBAN

173 e, and compared 8 SENV isolates, 6 prototype TTV isolates, and 7 TTV variants (including SANBAN, TUS0

174 An increase in PSMA TTV by at least 30% was associated with worse OS (median

175 multivariable analysis, only increased PSMA TTV and PSA progression remained independently prognosti

176 Conclusion: Change in quantitative PSMA TTV has strong potential as a prognostic biomarker with

177 monstrated in 95% (35/37) and a reduced PSMA TTV in 68% (25/37).

178 In this post hoc analysis, we quantified TTV load in sera of 76 KTRs, with 43 pausing mycophenoli

179 n and animal parvoviruses and of two related TTV-like viruses highly divergent from both the TTV and

180 In accordance with previous results TTV-DNA levels increase after lung transplantation reach

181 indicate that the human anellovirus species TTV and TTMDV are associated with fever in children, whi

182 ct humans, we found that anellovirus species TTV and TTMDV were more prevalent in the plasma and NP s

183 n patients with both increased PSA and SPECT TTV and patients with reduced SPECT TTV and PSA (median,

184 mo]), and 5 of 10 men had both PSA and SPECT TTV progression at week 12 (median PSA PFS, 2.8 mo [95%

185 Any increase in SPECT TTV between baseline and week 6 was associated with sign

186 An increase in SPECT TTV greater than 20% was also associated with PSA PFS (h

187 n PSA PFS in those with an increase in SPECT TTV was 3.7 mo (95% CI, 2.8-6.8), compared with 6.7 mo (

188 An increase of 30% or more in SPECT TTV was also associated with a shorter PSA PFS (hazard r

189 Any increase in SPECT TTV was associated with shorter PSA PFS (hazard ratio, 4

190 less significantly than any change in SPECT TTV.

191 5.8-10.6) in those with no increase in SPECT TTV.

192 Conclusion: Increasing SPECT TTV on quantitative (177)Lu SPECT predicts a short PFS a

193 Conclusion: Increasing PSMA SPECT TTV on quantitative (177)Lu SPECT/CT predicts short prog

194 nd SPECT TTV and patients with reduced SPECT TTV and PSA (median, 2.8 vs. 9.0 mo; P < 0.0001).

195 (177)Lu SPECT total tumor volume (SPECT TTV) was reduced in 68% (22/32; median, -0.20 m(3) [95%

196 In the patients with SPECT TTV progression at week 12, 50% (5/10) had no concurrent

197 In steady state TTV-DNA levels were significantly higher in patients wit

198 ction strategies now rarely allow for strong TTV constraints [S.

199 In summary, TTV-DNA might be used as an additional tool to monitor i

200 Recently it was found that swine TTV's (TTSuVs) can act as primary pathogens.

201 TV-specific PCRs, to determine whether swine TTVs (TTSuV) DNA can be detected in humans and vice vers

202 We conclude that TTV infection is present among North American blood dono

203 We conclude that TTV is a very common, often persistent infection that is

204 man serum into chimpanzees demonstrated that TTV can be transmitted to primates; no biochemical or hi

205 We hypothesize that TTV load could be an additional marker for immune functi

206 Taken together, these results indicate that TTV frequently infects Italian hemophiliacs treated with

207 1.34 g/ml; filtration studies indicated that TTV had a particle size of 30-50 nm.

208 ck of significant liver damage, suggest that TTV, similar to hepatitis G virus (HGV), may be an examp

209 However, some reports suggest that TTV-DNA levels reflect the grade of immunosuppression wi

210 The TTV and TF categories achieved an area under the receive

211 The TTV load was assessed in 342 serum samples by use of Taq

212 The TTV-DNA levels were not correlated with immunosuppressiv

213 However, the causative link between the TTV infection and liver disease remains uncertain.

214 -like viruses highly divergent from both the TTV and TTV-like minivirus groups.

215 netic analysis were used to characterise the TTV isolates.

216 haracteristic curve analysis established the TTV cutoff.

217 using primers from a conserved region in the TTV genome.

218 We investigated the TTV-DNA levels in 34 lung transplant recipients within t

219 To assess genetic heterogeneity of the TTV genome in more detail, a sequence analysis of PCR fr

220 ers generated from a conserved region of the TTV genome.

221 ive patients (n = 46) showed only 25% of the TTV levels measured in patients without AMR (P = 0.003).

222 intravenous drug abusers, only 1%-3% of the TTV-positive individuals were coinfected with GB virus C

223 quid biopsy did not accurately represent the TTV at CT.

224 from two initiating AUGs, and therefore, the TTV genome generates at least six proteins.

225 candidate selection could be expanded to the TTV (</=115 cm(3) )/AFP (</=400 ng/mL) criteria in cente

226 -18), and measured viral DNA loads using the TTV R-GENE kit (BioMerieux) and a pan-Anelloviridae in-h

227 more intense immunosuppression, whereas the TTV-DNA kinetic (ie, decrease of TTV-DNA levels) indicat

228 high degree of genetic complexity within the TTV population.

229 -A to E cases, the mean ALT was 182 in those TTV-positive and 302 in TTV-negatives.

230 ruses might suppress tumor formation through TTV-derived apoptosis-inducing protein (TAIP) and NF-kap

231 Thus, TTV exists as a "swarm" of at least five closely related

232 s (HEV) infection and could be vulnerable to TTV-associated adverse effects.

233 the coming years, astronomers will translate TTV observations into increasingly powerful constraints

234 The analysis used TTV-like minivirus as an outgroup, to determine a root o

235 er, the method of transit timing variations (TTVs) has blossomed as a new technique for characterizin

236 tems that exhibit transit-timing variations (TTVs).

237 The small DNA virus TTV was unexpectedly found in all culture-negative sampl

238 ntly described, including Torque teno virus (TTV) and Borrelia burgdorferi.

239 luding JC virus (JCV) and Torque teno virus (TTV) and interestingly, we detected multiple subtypes of

240 Torque teno virus (TTV) and Merkel cell polyomavirus (MCV) were detected by

241 an adenovirus (HAdV), and torque teno virus (TTV) DNAemia detected by quantitative real-time polymera

242 Quantification of torque teno virus (TTV) has been proposed as a surrogate parameter to monit

243 Torque Teno virus (TTV) is a ubiquitous infectious agent.

244 Torque teno virus (TTV) is part of the human virome.

245 The apathogenic torque teno virus (TTV) reflects the immunocompetence of its host and might

246 onstrated the presence of torque teno virus (TTV) sequences, compared with none in the controls (P=0.

247 Torque teno virus (TTV), from the Anelloviridae family, is proposed as a bi

248 ions of the anelloviruses torque teno virus (TTV), torque teno midi virus (TTMDV), and torque teno mi

249 prevalent and apathogenic Torque Teno virus (TTV), which might mirror the overall level of immunosupp

250 st has been proposed: the torque teno virus (TTV).

251 complete nucleotide sequence of this virus (TTV) isolated from the serum of a West African.

252 ed DNA virus, transfusion-transmitted virus (TTV), has been implicated as a cause of post-transfusion

253 virus, named transfusion-transmitted virus (TTV), was recently detected with high prevalence in Japa

254 NV) distantly related to the large TT virus (TTV) family was recently identified.

255 TT virus (TTV) has been proposed as the causative agent of non-A t

256 The prevalence of the blood-borne TT virus (TTV) in Italian hemophiliacs treated with different prep

257 TT virus (TTV) is a recently discovered infectious agent originall

258 TT virus (TTV) was recently identified in the serum of a patient w

259 Two overlapping sets of TT virus (TTV)-specific polymerase chain reaction primers were use

260 vovirus and two viruses related to TT virus (TTV).

261 A novel DNA virus, TT-virus (TTV), has been reported in patients with non-A-G posttra

262 Nonpathogenic torque teno viruses (TTVs) are highly prevalent in transplant recipients and

263 Torque Teno Viruses (TTVs) are ubiquitous DNA viruses in humans but not found

264 Torque Teno Viruses (TTVs) are ubiquitous viruses which are highly prevalent

265 cludes human and animal torque teno viruses (TTVs) with extensive genetic diversity.

266 itionally, patient-based total tumor volume (TTV) (sum of PSMA-positive tumor volumes) and total tumo

267 alysis tracked change in total tumor volume (TTV) and SUV.

268 haracteristics including total tumor volume (TTV) and up-to-7 criteria were recorded.

269 ent of the change in the total tumor volume (TTV) on the 4-h [(177)Lu]Lu-PSMA SPECT/CT after the firs

270 SPECT total tumor volume (TTV) was reduced between baseline and week 6 in 74% (71/

271 lysis was used to assess total tumor volume (TTV), enhancing tumor volume (ETV), and enhancing tumor

272 The total tumor volume (TTV), representing CT tumor burden, was calculated by ad

273 ce in the estimations of total tumor volume (TTV), total tumor cellularity (TTC), and tumor status wa

274 essment of PSMA-positive total tumor volume (TTV).

275 the previously proposed total tumor volume (TTV; </=115 cm(3) )/alpha-fetoprotein (AFP; </=400 ng/mL

276 nvestigated the role of total tumor volumes (TTVs) and new lesions (NLs) determined by LuPSMA SPECT/C

277 responders than in poor responders, whereas TTV(bone) increased in both groups during treatment.

278 We sought to determine whether TTV infection occurs in North American blood donors and

279 This study cannot distinguish whether TTV is a direct intraocular pathogen, an adjuvant for in

280 n lend importance to the question of whether TTV's can cross-infect across species.

281 liver disease in the UK to find out whether TTV infection is associated with liver damage.

282 infected with HCV alone, regardless of which TTV PCR protocol was used.

283 in UK blood donors, and the extent to which TTV contaminates blood products such as factor VIII and

284 were elevated in 2 of 27 patients (7%) with TTV alone compared with 43 of 56 patients (77%) coinfect

285 l-time polymerase chain reaction, along with TTV genogroups and coinfection with HEV.

286 with 43 of 56 patients (77%) coinfected with TTV and HCV and compared with 16 of 21 patients (76%) wi

287 rity of hepatitis in persons coinfected with TTV and HCV when compared with those infected with HCV a

288 s C, 40.0% were simultaneously infected with TTV.

289 d, whereas only 1 (4.5%) of 22 patients with TTV greater than 200 cm were successfully downstaged.

290 Patients with TTV less than 200 cm may be considered good candidates f

291 Fifty-two (76%) of 68 patients with TTV less than 200 cm were successfully downstaged, where

292 In KTRs with MPA withdrawal, TTV load decreased significantly from a median (interqua

293 In patients with MPA withdrawal, TTV load was significantly inversely correlated with COV

294 higher for patients beyond Milan, but within TTV/AFP (16 of 38; 42.1%), than for those within Milan (

295 within Milan and 38 beyond Milan, but within TTV/AFP.

296 lan criteria, and 32 beyond Milan but within TTV/AFP.

297 ompared to patients beyond Milan, but within TTV/AFP.

298 78 hemophilic patients (mean age, 29 years), TTV-DNA was found in 123 (69%), in comparison to 22 of 1